Nestlé, Israel’s Epitomee Medical Partner To Develop Weight Loss Capsule

Nestlé Health Science, a global leader in nutritional science, and Epitomee Medical, the Israel-based bio-medical company developing treatments for the overweight and obese population based on a gastric retention platform, have announced they have entered an agreement to develop and commercialize a weight loss and metabolic health product.

The two companies will partner to promote the polymer-based ingestible product developed by Epitomee Medical, by using Nestle’s widespread sales and marketing channels to launch the product to global markets.

The Swiss company will retain commercial rights the product.

The polymer-based ingestible product is aimed at promoting weight loss and improving health. It has already demonstrated efficacy and safety in various pre-clinical and clinical studies with significant weight loss reduction and other beneficial health impacts, the companies said in a statement.

“Nestlé Health Science is an ideal strategic partner for Epitomee. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders will be instrumental to Epitomee’s worldwide commercialization success,” said Dan Hashimshony PhD, CEO of Epitomee.

Founded in 2005, Epitomee Medical has developed a proprietary, ingestible device in the form of an easy to administer capsule that induces a feeling of satiety and reduces caloric intake to address metabolic disorders. The company’s gastric retention platform balances ingestible devices and the body’s natural mechanism to tackle chronic diseases. Epitomee’s first product is a drug-free, self-adminstered capsule which aims to prevent diabetes, address obesity-related issues and establish a healthier lifestyle.

“The research and development that Epitomee is doing is very promising. We look forward to working together to realize the commercialization of the product, an innovative approach to reducing weight and managing other associated metabolic health co-morbidities,” said Hans-Juergen Woerle, chief scientific & medical officer of Nestlé Health Science.

“We are excited about the opportunity that this deal brings to Epitomee and to the many millions of people around the world with obesity and other metabolic issues. This transformational deal is another recognition of the good science, the hard work, commitment and vision of our team,” Hashimshony added.

Based in Switzerland, Nestlé Health Science, a subsidiary of Nestle, offers an extensive consumer health portfolio of industry-leading medical nutrition, as well as consumer and VMS brands that are science-based solutions covering all facets of health, from prevention to maintenance, and all the way to treatment. The company employs over 5,000 people around the world.

Epitomee grants Nestlé Health Science exclusive and global commercial rights to use the product in the weight loss market, and potentially to address other disorders including prediabetes and Type 2 Diabetes under the terms of the agreement.